- List
- By Topic
- On Map
- Search Details

topotecan AND bevacizumab AND ovarian cancer
Need help? See RSS Feeds
Choose a feed type:

topotecan AND bevacizumab AND ovarian cancer (10 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT00097019 | Completed | A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed |
|
|
Interventional |
Phase 2 |
|
Industry |
|
53 | Female | 18 Years and older (Adult, Older Adult) | NCT00097019 | AVF2949g | February 2005 | May 2006 | May 2006 | November 18, 2004 | May 16, 2017 | |||||
2 | NCT00343044 | Completed Has Results |
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
40 | Female | 18 Years and older (Adult, Older Adult) | NCT00343044 | 3040200 AVF3648s |
June 2006 | January 2010 | August 2011 | June 22, 2006 | May 15, 2015 | May 15, 2015 |
|
||
3 | NCT03367182 | Completed | Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer |
|
|
Observational |
|
Other |
|
|
50 | Female | 18 Years and older (Adult, Older Adult) | NCT03367182 | 4-2017-0748 | REBECA | September 1, 2017 | January 31, 2018 | January 31, 2018 | December 8, 2017 | January 11, 2019 |
|
|||
4 | NCT00976911 | Completed Has Results |
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
361 | Female | 18 Years and older (Adult, Older Adult) | NCT00976911 | MO22224 2009-011400-33 |
October 2009 | July 2014 | July 2014 | September 15, 2009 | February 25, 2015 | February 25, 2015 |
|
||
5 | NCT00583622 | Terminated Has Results |
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
13 | Female | 18 Years to 70 Years (Adult, Older Adult) | NCT00583622 | 2007-0368 | December 2007 | January 2012 | January 2012 | December 31, 2007 | May 21, 2013 | May 21, 2013 |
|
||
6 | NCT03763123 | Recruiting | A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
48 | Female | 18 Years and older (Adult, Older Adult) | NCT03763123 | SIM-63-OC-101 | April 24, 2018 | December 31, 2019 | December 31, 2020 | December 4, 2018 | December 4, 2018 |
|
|||
7 | NCT03632798 | Recruiting | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
300 | Female | 18 Years and older (Adult, Older Adult) | NCT03632798 | CG02EOC | ACSCO | August 1, 2018 | July 30, 2021 | January 31, 2022 | August 15, 2018 | January 8, 2019 |
|
||
8 | NCT02312245 | Recruiting | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
|
|
Interventional |
Phase 2 |
|
Other / NIH |
|
|
240 | Female | 18 Years and older (Adult, Older Adult) | NCT02312245 | MC1463 NCI-2014-02399 Mod14-002986-03 P30CA015083 |
July 21, 2015 | June 2020 | June 2020 | December 9, 2014 | July 9, 2018 |
|
|||
9 | NCT01652079 | Completed | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
63 | Female | 18 Years and older (Adult, Older Adult) | NCT01652079 | 11-485 | April 2012 | March 2018 | March 2018 | July 27, 2012 | July 2, 2018 |
|
|||
10 | NCT02502266 | Recruiting | Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
|
|
Interventional |
Phase 2 Phase 3 |
|
NIH |
|
|
680 | Female | 18 Years and older (Adult, Older Adult) | NCT02502266 | NCI-2015-00651 s16-01681 NRG-GY005 U10CA180868 |
February 5, 2016 | June 30, 2023 | July 20, 2015 | February 21, 2019 |
|
† Study has passed its completion date and status has not been verified in more than two years.